Hospital-acquired pneumonia medical therapy
Hospital-acquired pneumonia Microchapters |
Differentiating Hospital-Acquired Pneumonia from other Diseases |
Diagnosis |
Treatment |
Case Studies |
Hospital-acquired pneumonia medical therapy On the Web |
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy |
Directions to Hospitals Treating Hospital-acquired pneumonia |
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2]
Overview
Antimicrobial therapy
Patients prone to Methicillin-resistant staphylococcus aureus
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic choice for MRSA
- Vancomycin
- Linezolid
- Teicoplanin
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Supportive trial data Wunderink RG, Niederman MS, Kollef MH; et al. (2012). "Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study". Clin. Infect. Dis. 54 (5): 621–9. doi:10.1093/cid/cir895. PMID 22247123. Unknown parameter |month=
ignored (help)
Side-effects of Linezolid
- Thrombocytopenia
- Gastrointestinal side-effects
- Renal dysfunction
Side-effects of vancomycin
- Renal toxicity were more common in vancomycin compared to linezolid